Product category:
Laboratory and scientific books and publishing
News Release from: Frost and Sullivan | Subject: World Stem Cell Therapeutics Markets M067- 52
Edited by the Laboratorytalk Editorial
Team on 23 February 2007
World stem cell therapeutics markets
Increased funding and developing regulatory framework provide impetus to stem cell therapeutics market
Stem cell research is among the most exciting frontiers of medical science as it promises to cure a number of debilitating disorders Not surprisingly then, several start-ups with innovative research programmes covering a wide range of therapeutic disorders have already been established
This article was originally published on Laboratorytalk on 2 Aug 2002 at 8.00am (UK)
Related stories
Smart materials: the new frontier of technology
Analysis reveals the advances made in the development of industrial applications for smart, active, or engineered materials, including their use in smart structures
Ready for convergence?
The convergence of nanotechnology, biotechnology, information technology, and cognitive science will have a substantial impact on companies and markets in the future
And, despite several regulatory, social, ethical, scientific and financial hurdles, funding increases and developing regulatory frameworks are supporting the expansion of the global stem cell therapeutics market.
Stem cells are being investigated for the treatment of several disorders, such as Parkinson's disease and cancer, which currently have no cure.
Adult stem cell therapies have been around in the market for three decades now but their application has been limited.
Further reading
European cardiac risk assessment markers
Elevated European CHF mortality rates and introduction of premium-priced assays stimulate uptake of cardiac risk assessment markers, according to new research
Bubble bursts in defoamer market
Negative growth will force European pulp and paper defoamer suppliers to recognise commodity market, says new report
Banking on blood
The blood banking devices market will continue to post steady figures, aided by the industry's flexibility and adaptability to changing market needs and technological advancements
On the other hand, embryonic stem cells are widely regarded as the proverbial holy grail of medical science.
"An ageing population and the lack of effective therapies for numerous disorders, apart from an increase in R+D funding will be the main drivers in the world stem cell therapeutics market," opines Frost and Sullivan research analyst Sumanth Kambhammettu in a recent study on world stem cell therapeutics markets.
"An improving regulatory environment in some countries coupled with newer applications will further boost market prospects".
Finally, ongoing efforts to boost government funding for stem cell research by certain states in the USA (such as California) and other countries in Europe and Asia will contribute to market growth".
However, a multitude of scientific, ethical, social and financial challenges continue to beset the commercialisation of stem cells.
Currently, regulatory frameworks in most countries are at an evolutionary stage, and market participants may find it difficult to prove the benefits of stem cell therapies over existing drugs and secure reimbursement.
In addition, human clinical trials of stem cell therapies may also pose a problem.
"Embryonic stem cell research has been mired in controversy with opposition from several ethical and social quarters besides which the science surrounding embryonic stem cells is itself in a very nascent stage," says Kambhammettu.
"In addition, owing to the high cost of development, these therapies are expected to be very expensive, and procuring reimbursement could be an uphill task".
To support rapid market development and improve their chances of success in a high-risk market, participants need to focus on developing stronger proof-of-principle models.
Strategic alliances with hospitals and medical centres of excellence will also provide synergistic benefits to both parties.
World stem cell therapeutics markets is part of the Frost pharmaceutical and biotechnology subscription, which also includes research in the following markets: European central nervous system (CNS) therapeutics markets, European antidepressant markets and European cancer markets.
All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
